SCHEMBL3323863

SCHEMBL3323863

COC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1c1cc(OC)ccc1OC

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.84
HSD17B10 Q99714 6/20 0.79
TP53 P04637 1/20 0.79
POLB P06746 1/20 0.79
ALDH1A1 P00352 5/20 0.64
HPGD P15428 3/20 0.64
MAPT P10636 2/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
MC4R P32245 1/20 0.64
CYP2C19 P33261 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
CASP1 P29466 4/20 0.58
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
CASP7 P55210 3/20 0.57
GAA P10253 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12135798 0.91 KDM4E (1.00) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3326112 0.89 KDM4E (0.75) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3324646 0.85 KDM4E (0.80) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3329684 0.84 HSD17B10 (0.69) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3323749 0.83 KDM4E (0.86) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3325408 0.82 KDM4E (0.65) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3329695 0.82 ALDH1A1 (0.79) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3003580 0.81 KDM4E (0.82) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3325660 0.81 KDM4E (0.57) KDM4EHSD17B10TP53POLBALDH1A1
SCHEMBL3323322 0.78 KDM4E (0.59) KDM4EHSD17B10TP53POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885HSD17B10 1530/4885TP53 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.